These tumors are experimental models used to compare the imaging properties of bispecific with monospecific agents under conditions of homogeneous or heterogeneous receptor expression but these conditions may not reflect the levels of these receptors or the receptor heterogeneity found in tumors in patients with HER2-positive BC. This evidence concerns the gene ERBB2 and breast cancer.